FLB Stock Overview
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
My Notes
NewNotes are coming soon
Standard BioTools Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.93 |
52 Week High | US$3.59 |
52 Week Low | US$0.92 |
Beta | 1.31 |
1 Month Change | 72.27% |
3 Month Change | 58.75% |
1 Year Change | -32.65% |
3 Year Change | -45.42% |
5 Year Change | n/a |
Change since IPO | -83.22% |
Recent News & Updates
Recent updates
Shareholder Returns
FLB | DE Life Sciences | DE Market | |
---|---|---|---|
7D | 4.6% | 2.6% | 0.3% |
1Y | -32.6% | -19.9% | -11.1% |
Return vs Industry: FLB underperformed the German Life Sciences industry which returned -18.5% over the past year.
Return vs Market: FLB underperformed the German Market which returned -10.1% over the past year.
Price Volatility
FLB volatility | |
---|---|
FLB Average Weekly Movement | 14.1% |
Life Sciences Industry Average Movement | 6.0% |
Market Average Movement | 5.2% |
10% most volatile stocks in DE Market | 10.5% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: FLB is more volatile than 90% of German stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: FLB's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 615 | Michael Egholm | https://www.fluidigm.com |
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system.
Standard BioTools Inc. Fundamentals Summary
FLB fundamental statistics | |
---|---|
Market Cap | €150.59m |
Earnings (TTM) | -€164.73m |
Revenue (TTM) | €100.66m |
1.5x
P/S Ratio-0.9x
P/E RatioIs FLB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
FLB income statement (TTM) | |
---|---|
Revenue | US$109.19m |
Cost of Revenue | US$98.00m |
Gross Profit | US$11.19m |
Other Expenses | US$189.87m |
Earnings | -US$178.68m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -2.25 |
Gross Margin | 10.25% |
Net Profit Margin | -163.64% |
Debt/Equity Ratio | 26.0% |
How did FLB perform over the long term?
See historical performance and comparison